#Obesity medicine
Chronic weight management as a clinical specialty.
Foundayo's $98 million launch quarter
Lilly reported $98 million in Q2 revenue for oral GLP-1 Foundayo. The filing shows an early launch, not proof that the medicine disappointed.
GLP-1 Drugs and Skin Disease Evidence
A 2026 review finds the strongest GLP-1 skin evidence in psoriasis, while most other dermatology uses remain observational.
Do GLP-1 Drugs Affect Muscle and Bone?
A 2026 meta-analysis found a low-certainty lean-mass signal with GLP-1 drugs, but no adjusted effect on bone or joint outcomes.
Semaglutide in type 1 diabetes: ADJUST-T1D
ADJUST-T1D found better glucose-and-weight outcomes with semaglutide in selected adults, but it did not test long-term cardiovascular benefit.
Tirzepatide anhedonia: three case reports
Three patients reported improved motivation after tirzepatide dose reduction, but the uncontrolled case series cannot establish frequency or causation.
GLP-1 drugs in dermatologic disease
A 2026 review links GLP-1 drugs with inflammatory skin disease, but its clearest clinical evidence comes from one psoriatic arthritis trial.
Retatrutide access opens case by case
A US registry now lists individual-patient retatrutide expanded access as available under narrow criteria. It is not approval or broad availability.
Semaglutide carbon model: what it found
A UK model estimated slightly lower lifetime emissions in two obesity populations but higher emissions with established cardiovascular disease.
GLP-1 Drugs and Anesthesia Safety
A 2026 study compared anesthesia outcomes for lipoabdominoplasty patients taking semaglutide or tirzepatide against those who were not.
Incretin Drugs and the Sarcopenia Question
A new review argues that incretin drugs such as tirzepatide and semaglutide need built-in muscle monitoring alongside fat-loss tracking.
Novo sues Lilly over GLP-1 ad claims
Novo Nordisk sued Eli Lilly over GLP-1 ads it says compare Zepbound with lower-dose Wegovy. Here is what the false-advertising suit alleges.
CT130: A GLP-1 Drug Built to Take Breaks
CT130 is a semaglutide-derived GLP-1 drug tested so far in mice and monkeys, not humans, built around scheduled drug-free intervals.